Aktienanalyse zu Zevra Therapeutics Inc (ZVRA)ZVRAZevra Therapeutics Inc

Zevra Therapeutics, Inc. is a commercial-stage rare disease company with a late-stage pipeline committed to bringing therapeutics to people living with rare diseases. Its commercial products and active development assets are MIPLYFFA, Arimoclomol, OLPRUVA, and Celiprolol. Its lead product, Niemann-Pick disease type C (NPC), is a rare, progressive neurodegenerative disorder. NPC is an ultra-rare and progressive neurodegenerative disease characterized by an inability of the body to transport cholesterol and lipids inside of cells. OLPRUVA (sodium phenylbutyrate) for oral suspension is approved in the United States as adjunctive therapy to standard of care, which includes dietary management, for the chronic management of UCDs involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase. Celiprolol is a selective adrenoceptor modulator (SAM). Celiprolol is approved in certain EU states for the treatment of hypertension and angina. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Zevra Therapeutics Inc is currently a hold due to mixed signals. The current price is $11.565, while the forward P/E ratio stands at 11.19, indicating reasonable valuation. However, the RSI is at 45.48, suggesting the stock is nearing oversold territory but not yet a strong buy signal. The recent earnings report showed a significant EPS surprise of 212.5%, with reported EPS at $0.25, which is a positive indicator. Yet, the negative opinion from the EMA regarding the drug application poses a risk, as it could impact future revenue growth. The stock has seen a 5-day change of -2.57%, reflecting recent volatility.